Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA.

Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25.

2.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

3.

Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.

Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M, Golemis EA.

Cancer Res. 2010 Nov 1;70(21):8907-16. doi: 10.1158/0008-5472.CAN-10-0353. Epub 2010 Oct 12.

4.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
5.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

6.

Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N.

Cell Cycle. 2009 Jun 15;8(12):1921-9. Epub 2009 Jun 15.

PMID:
19440047
7.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

8.

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.

Li J, Hong MJ, Chow JP, Man WY, Mak JP, Ma HT, Poon RY.

Oncotarget. 2015 Apr 20;6(11):9327-40.

9.

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.

Cancer Res. 2007 Mar 15;67(6):2800-8.

10.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

11.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

12.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, Ocaña A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

13.

Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB.

Mol Cancer Ther. 2010 Aug;9(8):2322-32. doi: 10.1158/1535-7163.MCT-09-1212. Epub 2010 Aug 3.

14.

Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.

Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB.

Anticancer Drugs. 2013 Mar;24(3):237-50. doi: 10.1097/CAD.0b013e32835d29fd.

15.

Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner.

Cicha I, Zitzmann R, Goppelt-Struebe M.

Int J Biochem Cell Biol. 2014 Jan;46:39-48. doi: 10.1016/j.biocel.2013.11.014. Epub 2013 Nov 22.

PMID:
24275091
16.

Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.

Hingorani P, Zhang W, Gorlick R, Kolb EA.

Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657. Epub 2009 May 15.

17.

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D.

Biochem Pharmacol. 2011 Apr 1;81(7):881-90. doi: 10.1016/j.bcp.2011.01.017. Epub 2011 Feb 1.

18.

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.

Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):531-8. doi: 10.1016/j.jtcvs.2012.10.041. Epub 2012 Nov 9.

19.

Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.

Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.

Carcinogenesis. 2012 Feb;33(2):285-93. doi: 10.1093/carcin/bgr278. Epub 2011 Nov 24.

20.

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE.

Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14.

Supplemental Content

Support Center